We re trying to expand our test menu in diagnostics, putting more tests onto our systems in the hospital segment. In the life sciences area, particularly with the human genome being mapped, there s going to be all kinds of opportunity for both new platforms and new technologies. We think that we might be spending proportionally more money on these new technologies. Our market is driven a lot by automation and productivity. The diagnostics market is always under scrutiny to manage costs.
Automation is a key means to manage costs and to increase productivity.
We also have automation for life science research, which has a different attribute, mainly high-throughput drug discovery testing. So automation fulfills two functions, one is productivity enhancement and cost savings, and the other is outcome-based doing more testing faster. That s one trend for sure. Another trend we see is that new therapeutic treatments will probably be accompanied by more diagnostic testing that enables you to stratify patients and predict the utility of the therapy. The whole outgrowth of DNA mapping is a promising area.